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Glucocorticoids (GCs) are steroids with profound anti-in-
flammatory and immunomodulatory activities. Synthetic GCs
are widely used for managing chronic inflammatory and auto-
immune conditions, as immunosuppressants in transplanta-
tion, and as anti-tumor agents in certain hematological cancers.
However, prolonged GC exposure can cause adverse effects.
A detailed understanding of GCs’ mechanisms of action may
enable harnessing of their desirable actions while minimizing
harmful effects.Here, we review the impact on theGCbiology of
microRNAs, small non-coding RNAs that post-transcription-
ally regulate gene expression. Emerging evidence indicates that
microRNAsmodulate GC production by the adrenal glands and
the cells’ responses to GCs. Furthermore, GCs influence cell
proliferation, survival, and function at least in part by regulating
microRNA expression.We propose that the beneficial effects of
GCs may be enhanced through combination with reagents tar-
geting specific microRNAs.
Both the fields of glucocorticoid (GC)3 biology and microRNA
biology are too vast and complex to survey in detail here.
Instead, we will give brief overviews of both areas, drawing
attention to excellent recent reviews, before focusing on the
functional interactions between GCs and microRNAs, which
have not been comprehensively reviewed elsewhere to our
knowledge.
Glucocorticoids
GCs are a group of steroid hormones that have varied roles in
development, homeostasis, and circadian regulation of physio-
logical processes (1–5). Among many effects, they suppress
inflammatory gene expression in several cell types and promote
apoptosis of some hematopoietic cells. These anti-inflamma-
tory and/or immunosuppressive effects are the basis of the
widespread use of synthetic glucocorticoids to prevent trans-
plant rejection and graft versus host disease and to treat chronic
inflammatory disorders and hematological malignancies (6).
However, severe, even life-threatening side effects can arise
from prolonged exposure to synthetic glucocorticoids, as well
as from elevated production of endogenous glucocorticoids, as
seen in the rare endocrine cancers known as Cushing’s disease.
Common side effects include osteoporosis, hypertension, mood
disorders,muscle and skin atrophy, and increased susceptibility
to infection. Although these side effects are often said to limit
the clinical utility of GCs, prolonged treatment with GCs is far
from uncommon, particularly among the elderly. Since the dis-
covery of GCs by Philip Hench and others in the 1940s, the
uncoupling of their desirable anti-inflammatory or immuno-
suppressive effects from their harmful side effects has been pur-
sued with little success (7).
The production and actions of GCs are subject to tight reg-
ulation at several levels. Here, we will briefly mention some of
these complex processes and direct interested readers to more
comprehensive reviews (2–5). 1) Like the related hormone
aldosterone, the GC cortisol is produced from the precursor
cholesterol in the adrenal cortex, via sequential enzymatic reac-
tions mediated by hydroxysteroid dehydrogenases (HSD fam-
ily) and cytochrome P450 oxidases (CYP family) (Fig. 1). Corti-
sol biosynthesis is regulated in circadian fashion by a hormonal
relay system known as the hypothalamic–pituitary–adrenal
(HPA) axis. The hypothalamus produces corticotropin-releas-
ing hormone, which acts upon the anterior pituitary to induce
production of adrenocorticotropic hormone (ACTH). ACTH
stimulates the adrenal gland to synthesize and release GCs,
principally cortisol in humans. Cortisol also acts on both the
hypothalamus and pituitary glands to suppress the HPA axis
and limit its own production via negative feedback. 2) Local GC
availability is regulated by interconversion between the active
GC cortisol and inactive cortisone (8). The conversion of corti-
sol to cortisone is chiefly mediated by 11-hydroxysteroid
dehydrogenase 2 (11HSD2), whereas the reverse reaction is
chiefly performed by 11HSD1. 11HSD2 is most strongly
expressed in the kidney, where it protects the aldosterone
receptor from inappropriate activation by GCs. Expression of
11HSD1 in many cells and tissues promotes GC responsive-
ness. 3) The GC receptor (GR) is encoded by theNr3c1 gene in
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mice (NR3C1 in humans). Alternative transcription initiation
and splicing generate a variety of mRNA species (3). These
mRNA isoforms, in addition to alternative use of translational
initiation sites, generate GR protein products that differ in
function. 4) GR is a transcription factor, which is thought to
exert most of its effects at the level of transcriptional control
(although non-genomic effects are also increasingly recog-
nized). In the absence of ligand, GR is held in the cytoplasm in
complex with chaperone proteins, including FKBP5 (FK506-
binding protein 5), whichmaintain its ligand–receptive confor-
mation but also mask its nuclear localization signal. GCs are
lipophilic and readily diffuse across the plasma membrane.
Binding to GR causes the release of GR from its chaperone
complex and translocation to the nucleus. 5) GR can bind
directly to DNA, most often as a homodimer recognizing
a palindromic element with consensus half-site sequence
AGAACA. It can also bind to DNA as a monomer recognizing
a single half-site, or it can be recruited to DNA indirectly, via
interaction with various other DNA-binding proteins. Which-
ever mode of binding to DNA is used, GR may regulate tran-
scription either positively or negatively, depending on cellular
and chromatin context. Higher order chromatin structure and
the presence of DNA-bound partner proteins dictate where GR
is recruited and which genes it is able to regulate. Most of the
GC regulome is cell type-specific, and relatively few genes are
universallyGC-responsive. 6)GR is extensively phosphorylated
within its N-terminal half (1). A few of its phosphorylation sites
have been functionally characterized and shown to modulate
GR function, either globally or in a target gene-specificmanner.
Other post-translational modifications such as SUMOylation
have also been described.
MicroRNAs
MicroRNAs (miRNAs) are short RNA species, generally
19–22 nucleotides in length, which mediate post-transcrip-
tional down-regulation of protein expression (9). This occurs
by sequence-specific recognition of seed sequences predomi-
nantly in the 3UTRof targetmRNAs. Regulation via 5UTRsor
even open reading framesmay also occur, but it is poorly under-
stood and believed to be rare (10, 11). Themajority of mamma-
lian miRNA/mRNA interactions result in mRNA degradation,
brought about by transcript deadenylation through recruit-
ment of the CCR4–NOT deadenylation complex (9, 12). Alter-
natively, translational repression can occur due to inhibition of
translational initiation (13), in at least some cases as a conse-
quence of mRNA deadenylation. Up to 60% of the mammalian
transcriptome is estimated to be subject to regulation by
miRNAs (9, 14).
The miRNAs are generally transcribed from the genome by
RNA polymerase II (Fig. 2). They can be expressed from within
protein–coding genes, most often from their introns or
3UTRs; from miRNA clusters, where multiple miRNAs are
generated from a single precursor transcript; or as single
miRNAs within non-coding regions. They are synthesized as
initial extended RNA transcripts, called primary miRNAs. The
initial transcript undergoes its first round of processing by the
RNase III enzyme Drosha and associated protein Pasha/
DGCR8 (DiGeorge syndrome critical region 8), which cleave it
into the 70-nt precursor miRNA. This is transported out of the
nucleus and undergoes a second round of cleavage, performed
by the RNase III enzyme Dicer, resulting in the mature miRNA
as a duplex around 21 nts in length (15). The miRNA functions
as part of an RNA-induced silencing complex (RISC), in which
theArgonaute family of proteins plays amajor role. Themature
miRNA is loaded onto Argonaute (Ago1–4 in mammals), and
the passenger strand is removed and degraded, resulting in the
final active complex containing a one-strandedmiRNA species
complementary to a portion of the target gene 3UTR. The
regulation of strand selection in miRNA maturation is not yet
fully understood. There is increasing evidence that either
strand of the miRNA duplex can be selected as a guide for Ago
Figure1. RegulationofGCbiosynthesis bymiRNAs. The endogenous humanglucocorticoid cortisol and themineralocorticoid aldosterone are synthesized
in the adrenal cortex from cholesterol. miRNAs have been reported to regulate this synthesis by the targeting of cytochrome p450 enzymes.
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proteins and independently regulate expression of distinct tar-
gets (16, 17).
Regulation of glucocorticoid availability bymiRNAs
Global inhibition ofmiRNAproduction by knockdownof the
processing enzyme Dicer increased the production of cortisol
by adrenocortical cells, implying that steroidogenesis is nega-
tively regulated by miRNAs (18, 19). Among mRNAs whose
expression significantly increased following Dicer knockdown
were CYP11A1, CYP11B1, and CYP17A1, which encode cyto-
chrome oxidase enzymes involved in cortisol biosynthesis or
interconversion between aldosterone and cortisol biosynthetic
pathways (Fig. 1). miR-24 andmiR-10b were implicated as neg-
ative regulators of CYP11B1 (19, 20), and miR-320a-3p as
a negative regulator of both CYP11A1 and CYP17A1 (18).
Although individual miRNAs exert relatively little effect on
cortisol biosynthesis, coordinated changes of miRNA abun-
dance may have a more striking impact, for example in the
context of hypoxia or adenocarcinoma (18, 20). Local GC
availability can also be regulated via effects of miRNAs on
expression of 11-HSD enzymes. miR-579 and miR-561
were identified as negative regulators of 11-HSD1 expres-
sion (21). In theory, differences in expression of these
miRNAs could have an impact on metabolic side effects of
GC excess (8, 22).
Regulation of the glucocorticoid receptor bymiRNAs
GCs regulate many aspects of neuronal development and
function, having particularly important roles in adaptation to
stress. Expression of GR is high in the hypothalamus and other
regions of the brain forming the primitive limbic system, which
is central to stress responses (23). Increased GR expression
improves resilience to at least some forms of experimental
stress (24). Physiologically, miRNA-mediated modulation of
GR expression is thought to play a role in fine-tuning responses
to GCs during development of the central nervous system
(25). Pathophysiologically, prolonged exposure to stress or
elevated GC levels can cause long-lasting reprogramming of
neuronal GC responses, which can result in neuropsychiat-
ric disorders such as depression in later life. Such repro-
gramming at critical developmental stages in uteromay con-
tribute to the transgenerational effects of antenatal GC
exposure (23, 26).
The 3UTR of the canonical Nr3c1/NR3C1 transcript con-
tains a number of well-conserved binding sites for miRNAs
(27), of which we will initially focus on miR-124-3p. This neu-
ronally expressed miRNA targets the Nr3c1 3UTR to down-
regulate GR expression (28–32). It can be induced by GCs (28,
32–34), suggesting that it may contribute to negative-feedback
regulation of GC sensitivity. In rats (31, 34) and mice (32), ele-
vated miR-124-3p levels in the brain were associated with
decreased GR levels and GC sensitivity and increased depres-
sion-like symptoms. Furthermore, treatment of mice with an
miR-124-3p antagonist (antagomir) reduced depression-re-
lated behaviors (32). Levels of miR-124-3p were reportedly ele-
vated in peripheral blood of patientswith severe depression (35,
36). Collectively, these findings suggest that miR-124-3p may
be both a biomarker and therapeutic target for psychiatric dis-
orders related to dysfunction of the HPA axis. It should be
noted that several other putative targets of miR-124 have been
identified (37), and miR-124 was reported to influence GR
function indirectly via effects on phosphodiesterase 4B (38) or
11HSD1 (34).
ACTH treatment ofmice increased adrenal gland expression
of several miRNAs, includingmiR-142-3p (although, curiously,
not miR-124-3p) (39). A number of these miRNAs were dem-
onstrated to target the Nr3c1 3UTR and reduce expression of
Figure 2.miRNAbiogenesis and function.miRNAs are transcribed from the genome to create primary (pri-)miRNAs. The first round of cleavage occurs in the
nucleus, carried out by the RNase III enzyme Drosha and associated factor Pasha/DGCR8, resulting in the shorter precursor (pre-)miRNA. Nuclear export is
mediatedbyExportin 5 (XPO5) andRan-GTP. The secondcleavage is carriedout in the cytoplasmby theRNase III enzymeDicer aspart of aprotein complex that
produces the mature miRNA. Strand selection results in release of one of the two miRNA strands, which is degraded. The retained strand is loaded onto
Argonaute protein (e.g. Ago2) and forms RISC along with other proteins such as GW182. Silencing can occur by promoting deadenylation and mRNA
degradation or translational repression.
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GR. As suggested above, miRNA-mediated fine-tuning of GR
levels may contribute to desensitization in the face of sustained
activation of the HPA axis, preventing consequences such as
GC-induced atrophy of the adrenal glands. Other miRNAs
that have been implicated in the post-transcriptional control
of GR expression include miR-101a andmiR-18a (31, 39, 40).
Increased expression of miR-18a and decreased expression
of GRwere found in the paraventricular nuclei of Fischer 344
rats, which fail to demonstrate adaptive responses to
repeated stress and display increases in stress-related disor-
ders (40).
An interesting concept is that differential exon usage at the
Nr3c1 locusmay generate transcripts that differ in their suscep-
tibility to miRNA-mediated regulation. Differential splicing at
the last intron gives rise to anmRNA isoform that encodesGR
but lacks binding sites for miR-124-3p, miR-142-3p, and others
(28). The GR protein isoform is transcriptionally inactive and
is believed to function as a dominant-negative inhibitor of the
canonical GR isoform (41). Therefore, either changes of
mRNA splicing or miRNA expression could result in an
increasedGR/GR ratio and an impairment in GC sensitivity.
Cell type-specific alternative promoter usage at the Nr3c1
locus generates transcripts containing variant, non-coding first
exons. It has been speculated but not yet established that these
mRNA isoforms differ in sensitivity to miRNA-mediated regu-
lation (42). Targeting of 5UTRs by miRNAs differs from the
canonical mechanism but has been demonstrated in other con-
texts (10).
High-dose GCs are often used to treat leukemias such as
multiple myeloma (MM) and acute lymphoblastic leukemia
(ALL) because of their capacity to impair cell division or pro-
mote apoptosis. Resistance to these effects is a common and
serious clinical problem. miRNA-mediated suppression of GR
has been identified as a possible causative event in the escape of
leukemias fromGC therapy (27, 43). Expression of miR-124-3p
was elevated in ALL patients that showed poor response to GC
therapy and was accompanied by reduced expression of GR
(44). Introduction of miR-124-3p to a GC-sensitive cell line in
vitro attenuated the anti-proliferative and pro-apoptotic effects
of GC treatment (44). High expression of miR-142-3p in ALL
was also correlated with poor prognosis (45). This miRNA was
shown to inhibit pro-apoptotic effects of GCs by targeting both
GC and cyclic AMP-signaling pathways, which cooperate to
regulate T cell apoptosis (45, 46). It appears that escape from
the inhibition of tumor growth may depend on miRNAs that
normally function to attenuate GC responses in the context of
sustained HPA axis dysregulation and/or GC excess. The high
concentrations of GCs used in cancer treatment may generate
selective pressure for cells expressing high levels of NR3C1-
targeting miRNAs or directly promote increases in expression
of those miRNAs. The miRNA-mediated regulation of GR
expression has also been implicated in the loss of GC sensitivity
in MM. The NR3C1-targeting miR-130b was more strongly
expressed in a GC-insensitive MM line, and its introduction to
aGC-sensitive line impaired cellular response toGC treatment,
including the induction of apoptosis (47). However, the use of
an antagomir to knock down miR-130b expression in the GC-
insensitive line was not sufficient to restore GC sensitivity, sug-
gesting that additional factors (miRNA or other) must contrib-
ute to GC resistance.
GR function is positively and negatively regulated via phos-
phorylation (1), and it can be indirectly modulated at this level
by miRNAs. For example, miR-9 targets a regulatory subunit of
protein phosphatase 2A (PP2A), leading to an increase in activ-
ity of the PP2A substrate c-Jun N-terminal kinase 1 (JNK1) and
enhanced phosphorylation of GR (48). Phosphorylation by
JNK1 impairs GR function by inhibiting nuclear translocation
of the receptor. An miR-9 antagonist restored GC responsive-
ness in experimental models of GC-resistant asthma (48).
Another indirect mechanism for modulation of GR function
involves miR-511-5p-mediated control of the expression of the
chaperone protein FKBP5, alleviating GR repression by this
chaperone and contributing to neuronal differentiation (49).
miR-433 was reported to dampenGR activity indirectly by sup-
pressing its ligand-induced translocation to the nucleus, but a
detailedmechanism underlying this miRNA effect has yet to be
described (50).
Role of miRNAs in leukocyte responses to
glucocorticoids
Several miRNAs have been implicated in positive or negative
regulation of inflammatory and immune responses (51, 52), and
such mechanisms may be subject to modulation by GCs. The
best characterized example is miR-155, which is generated
from the precursor transcript B cell integration cluster (BIC)
(53). Integration of the avian leukosis virus at the BIC locus in
chickens increased the expression of BIC and its product miR-
155, with oncogenic consequences. Increased levels ofmiR-155
have subsequently been described in many types of cancer,
leading to its identification as one of the first oncogenic
miRNAs (oncomirs). In myeloid cells, the expression of miR-
155 is induced by engagement of pattern recognition receptors,
in a manner that is at least partly dependent on nuclear factor
B (NF-B) (54, 55). It promotes inflammatory responses by
inhibiting the expression of negative regulators, including sup-
pressor of cytokine signaling 1 (SOCS1), a negative regulator of
type 1 cytokine and Toll-like receptors; Src homology 2-con-
taining inositol phosphatase 1 (SHIP1), a negative regulator of
the TLR/PI3K/Akt pathway; and Bcl6, a negative regulator of
NF-B (53). miR-155 is highly expressed in both fibroblasts and
macrophages of the inflamed synovium in rheumatoid arthritis
(RA), where it contributes to the elevated expression of chemo-
kines and pro-inflammatory cytokines (56, 57). Mice lacking
miR-155 were resistant to synovial inflammation and bone ero-
sion in an experimentalmodel of RA, identifying thismiRNA as
a critical inflammatory mediator (57). The GC dexamethasone
inhibited the lipopolysaccharide (LPS)-induced expression of
miR-155 in primary macrophages and macrophage cell lines
(54), spleen and liver cells of LPS-injected mice (54, 58), and T
lymphocytes of sepsis patients (59). These observations collec-
tively suggest down-regulation ofmiR-155 is an important anti-
inflammatory action of GCs. Dexamethasone-mediated down-
regulation of a BIC promoter construct in the macrophage cell
line RAW264.7 was dependent on an NF-B-binding site,
although curiously, the mutation of this site did not strongly
impair the activation of the promoter by LPS (54). The exact
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mechanism by which GCs inhibit miR-155 expression requires
further clarification. Another important question is whether
GCs alter B cell function via changes in expression of miR-155.
There is growing evidence for a pathogenic role of miR-155 in
Th2-mediated allergic diseases such as asthma (60), which are
commonly treated using GCs. However, miR-155 expression
was neither elevated in airway cells of patientswithmild asthma
nor was successful glucocorticoid therapy associated with any
change in its expression (61). In fact, noGC-induced changes of
miRNA abundance were found in this study or another from
the same group (62), in which pulmonary inflammation inmice
was induced by LPS inhalation. Either GC-mediated changes
of miRNA expression did not contribute strongly to the sup-
pression of inflammation in vivo, or the heterogeneity of cell
types sampled in lung biopsies concealed cell type-specific
GC responses.
miR-511 is generated from the fifth intron of Mrc1 mRNA,
which encodes the C-type mannose receptor CD206. Expres-
sion of CD206 is elevated in so-called alternatively-activated or
M2macrophages and can be up-regulated by GCs as well as the
M2-inducing cytokines IL-4 and -13 (63, 64). miR-511-5p was
shown to target Tlr4 (Toll-like receptor 4) and Il12b (IL-12p40
subunit), contributing to impaired sensitivity to LPS and
decreased expression of the classically-activated (M1) macro-
phage marker IL-12 (64). The SPRET/Ei mouse strain is resist-
ant to TNF-induced systemic inflammation and displays
hyperactivity of the HPA axis. The consequently high levels of
endogenous GCs increased the expression of miR-511-5p,
which targeted Tnfrsf1a mRNA to down-regulate its protein
product, the p55TNF receptor, conferring TNF resistance (63).
Thus, changes in levels of miR-511-5p or its opposite strand
partnermiR-511-3pmay have an important impact onmyeloid
cell differentiation and activation, as a by-product of altered
Mrc1 gene expression (65, 66). Another GC-induced miRNA,
miR-98, targetedTnfrsf1bmRNA and reduced expression of its
product, the p75 TNF receptor, in T lymphocytes (67). miR-98,
like other members of the let-7 miRNA family to which it
belongs, is also thought to target the 3UTR of Il13 (67, 68).
Because IL-13 has a well-established pathogenic role in asthma,
miR-98 may contribute to therapeutic effects of GCs in this
disease.
Mitogen-activated protein kinase (MAPK) p38 is a critical
mediator of inflammatory responses inmyeloid and other cells.
Its activity is dynamically regulated by a negative feedback loop
involving its dephosphorylation and inactivation by dual spec-
ificity phosphatase 1 (DUSP1) (69, 70). A number of pro-
and anti-inflammatory mediators influence the duration and
strength of inflammatory responses by modulating the expres-
sion of DUSP1 (70, 71). Notably, GCs cooperate with pro-in-
flammatory stimuli to enhance and sustain DUSP1 expres-
sion and to accelerate the inactivation of p38MAPK (69, 70).
Both direct GR-mediated activation of the Dusp1 gene (72,
73) and indirect miRNA-mediated effects (74) have been
described. Pro-inflammatory stimuli induce the expression
of miR-101, which targets the Dusp1 3UTR. GCs inhibit the
expression of miR-101, contributing to sustained DUSP1
expression, impaired p38 MAPK activation, and reduced
expression of p38 MAPK-dependent inflammatory media-
tors (74).
GCs influence lymphocyte cell division and apoptosis, effects
that can be exploited for the treatment of many hematological
malignancies. As reviewed elsewhere (43), tumor-suppressive
effects ofGCs are now thought to involve changes in expression
of miRNAs. The miRNAs that regulate GC responses by alter-
ing the expression of GR were discussed above. The miR-
1792 cluster consists of six miRNAs (miR-17, -18a, -19a,
-19b-1, -20a, and 92a-1) generated froma single precursor RNA
that is transcribed from chromosome 13 (75). The chromo-
somal region is duplicated in many human lymphomas, and
overexpression from a transgenic construct causes lymphopro-
liferative disease (76). Targets of themiRNA cluster include the
tumor suppressor PTEN (phosphatase and tensin homolog),
which regulates inositol phosphate signaling; and Bim, a pro-
apoptoticmember of the Bcl-2 family of proteins, which collec-
tively regulate cytochrome c-mediated apoptosis. Several
reports have ascribed therapeutic effects of GCs in lymphoma
to the suppression of the miR-1792 cluster, and consequent
inductionofBim-mediatedapoptosis(77–80).Conversely,resis-
tance to GC-induced apoptosis was associated with failure of
GCs to down-regulate the miR-1792 cluster (77, 81). This
miRNA cluster appears to play a well-conserved role in fine-
tuning of responses to pro- and anti-apoptotic signals. How-
ever, the mechanism of regulation by GCs remains to be
identified.
OtherGC-regulatedmiRNAs thatmay contribute to the reg-
ulation of survival have been identified by deep sequencing of
leukocytes undergoing GC-induced apoptosis (80, 82) or
screening for differentially expressed miRNAs in GC-sensitive
and -insensitive cancer cell lines (81, 83). One such differen-
tially expressedmiRNA ismiR-150-5p, whichwas up-regulated
in a GC-sensitive MM cell line but not in a GC-insensitive cell
line. Although overexpression of miR-150-5p in the GC-insen-
sitive line reprisedmany of the effects of GCs on genes involved
in proliferation and survival, it failed to induce apoptosis (81).
Additional effectors of the GC response therefore remain to be
identified. Conversely, resistance to GC-induced apoptosis in
MM has been linked to increased expression of miR-221/222
(84) or miR-125b (83). These miRNAs are likely to exert their
effects by impairing cell death pathways, including DNA dam-
age-induced apoptosis driven by TP53 (tumor protein 53). Par-
adoxically, miR-125b is up-regulated by GCs (83), perhaps a
mechanism by whichGCs self-limit their pro-apoptotic effects.
One implication of these observations is that therapeutic pro-
motion of apoptosis in hematological malignancies could be
augmented by supplementing GCs with miRNA antagonists
(83, 84). However, successful therapeutic manipulation of
miRNA expression is likely to be highly specific to tumor type
and mechanism of oncogenesis. This is demonstrated by the
comparison of miR-221 expression between cancers. Resis-
tance to GC-induced apoptosis has been attributed to an
increase of miR-221 expression in MM (84) but a decrease of
miR-221 expression in some forms of ALL (85).
Plasmacytoid dendritic cells (pDCs) are key to the innate
immune defense against viral pathogens. They express high lev-
els of type I interferons upon stimulation with agonists that
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mimic viral infection, such as ligands of Toll-like receptor 9
(TLR9). Such agonists render pDCs resistant to GC-induced
apoptosis (86). Treatment of pDCswithGCalone led to up-reg-
ulation of several miRNAs, including members of the miR-29
family that can target anti-apoptotic members of the Bcl2 fam-
ily. Addition of a TLR9 agonist abrogated GC-induced apopto-
sis, which was restored by transfection of miR-29b or miR-29c
mimics (87). Therefore, activation of pDCs impairs their GC-
induced apoptosis at least partly by inhibiting the expression of
miR-29 family members.
Role of miRNAs in non-hematopoietic cell responses to
glucocorticoids
Bone is continuously remodeled via balanced activities of
bone-forming cells (osteoblasts) and bone-resorbing cells
(osteoclasts). A common and severe side effect of prolonged
exposure to GCs is osteoporosis, resulting from decreased pro-
liferation or increased apoptosis of osteoblasts, combined with
increased proliferation or resorptive activity of osteoclasts (88).
Treatment of osteoblasts with GC decreased the expression of
the miR-1792 cluster (89). Both miR-17 and miR-20a inhibit
osteoblast expression of receptor activator of NF-B ligand
(RANKL), a factor critical for driving the differentiation and
activation of osteoclasts (90). Therefore, decreasedmiR-1792
expression could indirectly favor bone resorption. As
described in lymphoma cells, decreased miR-1792 expres-
sion also promotes Bim-mediated apoptosis of osteoblasts,
providing a direct mechanism of GC-induced bone loss
(89). Down-regulation of the miR-1792 cluster was also
reported to contribute to GC-induced apoptosis of chondro-
cytes, suggesting that this mechanism of control of apoptosis
may be widespread (91).
Several miRNAs have been reported to target components of
the Wnt (wingless type)-signaling pathway, which fine-tunes
bone metabolism (92, 93). miR-199a-5p is up-regulated by GC
treatment of osteoblasts and targets two members of theWNT
pathway, WNT2 and FZD4, a member of the Frizzled family
of plasma membrane WNT receptors (94). However, miR-
199a-5p levels were found to be diminished in bone samples
from patients with Cushing’s disease, a condition of endoge-
nous GC excess (95). The reason for the discrepancy is not
known. It could be related to the heterogeneous cellular com-
position of bone samples studied or an adaptation to prolonged
elevation of endogenous GC. miR-320b is also up-regulated by
GC treatment of osteoblasts, causing reduction in the expres-
sion of -catenin, the key downstreammediator ofWnt signal-
ing (96). Other candidate miRNA mediators of GC effects on
bonewere also identified in this study. ProlongedGC treatment
of rats decreased the expression in bone of several miRNAs,
including miR-29a (97). Retroviral delivery of miR-29a precur-
sor RNA protected rats against GC-induced bone loss, whereas
the miR-29a antagonist mimicked the effects of GC. Increased
levels ofmiR-29a were accompanied by increased expression of
osteogenicmarkers such as collagen type 1a1 and the transcrip-
tion factor Runx2. However, direct targets of miR-29a were not
identified. It was suggested that miR-29a could be utilized to
prevent bone pathologies associated with long-term GC use. A
note of caution is necessary here. Osteoblast-specific deletion
of the miRNA-processing enzyme Dicer did not prevent GC-
induced inhibition of bone formation (98). The most obvious
interpretation is that miRNAs do not play a major role in GC-
induced osteoporosis. However, it is also conceivable that
global disruption of miRNA biogenesis in osteoblasts has bal-
ancing positive and negative effects on bone turnover.
Several studies have reported a broad down-regulation of
mature miRNA expression in response to GC treatment. This
has been linked to the reduced expression of the miRNA pro-
cessing enzymes Drosha, Dicer, and Pasha/DGCR8, with a
resulting reduction in total miRNA maturation (78, 89, 91).
Silencing of Dicer expression by shRNA in lymphocytes en-
hanced the apoptosis induction byGCs (78). However, the gen-
eral consequences of a global inhibition of miRNA production
are unclear, due to the broad roles of miRNAs and the varied
context-specific effects of GCs. The proposed mechanism of
miRNA inhibition is also inconsistent with themultiple reports
of GC-inducedmiRNA up-regulation inmultiple cell types (67,
80, 95, 96) and the observations of transcriptional inhibition,
for example of the miR-1792 cluster (79). These studies do,
however, highlight the many potential mechanisms by which
GCs can alter miRNA abundance, either in a miRNA-specific
manner or more broadly.
Summary
As miRNAs exert such pervasive effects on biological pro-
cesses, it is not surprising that they touch on GC action at sev-
eral points (summarized in Fig. 3). Their touch is often light, in
the sense that individual miRNAs alter expression of their tar-
gets only modestly. Nevertheless, one miRNA can hit several
targets, and one target may be hit by several different miRNAs.
Therefore, coherent and coordinated changes of miRNA abun-
dance can affect complex biological processes quite profoundly.
Furthermore, functional interactions between miRNAs and
target transcripts are based on limited sequence complementa-
rity. Such regulatory complexity creates two sets of major chal-
lenges. The first are essentially challenges of methodology and
bio-informatics. How are functional interactions to be pre-
dicted with confidence, and how are subtle effects of individual
miRNAs to be experimentally validated without the danger of
confirmation bias? How are miRNA-mediated effects on bio-
logical processes to be identified and understood when they
involve many-to-many rather than one-to-one interactions?
These challenges are increasingly being met through improve-
ments in miRNA target prediction algorithms, systems biolog-
ical approaches, better methodologies, and more widespread
adoption of best-practice experimental controls. The second
set of challenges relate to the therapeutic exploitation of knowl-
edge gained. In this context, advances are likely to bemost rapid
in situations where insensitivity to GCs is a pressing clinical
problem, for example in hematological malignancies and GC-
resistant asthma. Even where good therapeutic targets can be
clearly identified, it remains to be seen whether a mimic or
antagonist of a single miRNA species will be sufficient to exert
therapeutic effects. If targeting more than one miRNA proves
necessary, this will create additional barriers to development, in
part because of the problem of predicting and mitigating off-
MINIREVIEW: Glucocorticoids andmicroRNAs
1870 J. Biol. Chem. (2018) 293(6) 1865–1874
 at The U
niversity of Birm
ingham
 on A
pril 18, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
target effects. This field of endeavor is an exciting one, but suc-
cess is far from certain.
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